Immune Dysregulation in Endometriomas: Implications for Inflammation
International Journal of Molecular Sciences · 28.04.2024 · 25 (9) · 4802
DOI: 10.3390/ijms25094802 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.04.2024. Verfasst von Izabela Dymanowska-Dyjak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Independent Laboratory of Minimally Invasive Gynecology and Gynecological Endocrinology, Medical University of Lublin, 20-081 Lublin, Poland. Hauptthemen laut MEDLINE: Endometriosis, Inflammation. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin.
Abstract (Originalsprache)
The most common manifestation of endometriosis, a condition characterized by the presence of endometrial-like tissue outside of the uterus, is the endometrioma, a cystic ovarian lesion. It is a commonly occurring condition associated with chronic pelvic pain exacerbated prior to and during menstruation, as well as infertility. The exact pathomechanisms of the endometrioma are still not fully understood. Emerging evidence suggests a pivotal role of immune dysregulation in the pathogenesis of endometriomas, primarily influencing both local and systemic inflammatory processes. Among the factors implicated in the creation of the inflammatory milieu associated with endometriomas, alterations in both serum and local levels of several cytokines stand out, including IL-6, IL-8, and IL-1β, along with abnormalities in the innate immune system. While numerous signaling pathways have been suggested to play a role in the inflammatory process linked to endometriomas, only NF-κB has been conclusively demonstrated to be involved. Additionally, increased oxidative stress, both resulting from and contributing to endometriomas, has been identified as a primary driver of both systemic and local inflammation associated with the condition. This article reviews the current understanding of immune dysfunctions in the endometrioma and their implications for inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Independent Laboratory of Minimally Invasive Gynecology and Gynecological Endocrinology, Medical University of Lublin, 20-081 Lublin, Poland.
- Department of Gynecological Oncology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland.
- Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland.
- Department of Vascular Surgery and Angiology, Medical University of Lublin, 20-081 Lublin, Poland.
- Chair and Department of Oral Surgery, Medical University of Lublin, 20-093 Lublin, Poland.
- Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland.
ORCID-Profile: Izabela Morawska-Michalska, Adam Michalski, Grzegorz Polak, Ewelina Grywalska
Förderung
- Medical University of Lublin
Zitieren
APA
Dymanowska-Dyjak, I., Terpiłowska, B., Morawska-Michalska, I., Michalski, A., Polak, G., Terpiłowski, M., Rahnama-Hezavah, M., & Grywalska, E. (2024). Immune Dysregulation in Endometriomas: Implications for Inflammation. International Journal of Molecular Sciences, 25(9), 4802. https://doi.org/10.3390/ijms25094802
Vancouver
Dymanowska-Dyjak I, Terpiłowska B, Morawska-Michalska I, Michalski A, Polak G, Terpiłowski M, et al. Immune Dysregulation in Endometriomas: Implications for Inflammation. International Journal of Molecular Sciences. 2024;25(9):4802. doi:10.3390/ijms25094802
BibTeX
@article{DymanowskaDyjak2024,
author = {Dymanowska-Dyjak, Izabela and Terpiłowska, Barbara and Morawska-Michalska, Izabela and Michalski, Adam and Polak, Grzegorz and Terpiłowski, Michał and Rahnama-Hezavah, Mansur and Grywalska, Ewelina},
title = {Immune Dysregulation in Endometriomas: Implications for Inflammation},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {9},
pages = {4802},
doi = {10.3390/ijms25094802}
}
EUVIMED